Dr. Sujuan Ba is the President & CEO, Founder of the Asian Fund for Cancer Research. She also serves as the President & CEO of the National Foundation for Cancer Research, the Co-founder & CEO of the AIM-HI Accelerator Fund, and the Co-Founder of the Global Coalition for Adaptive Research. She is one of the instrumental leaders in establishing GBM AGILE, the first-ever paradigm-shifting adaptive clinical trial platform for brain cancer and other rare cancers.
Dr. Ba has led the establishment of the Szent-Györgyi Prize for Progress in Cancer Research, an international prize recognizing outstanding scientific achievement in the war against cancer, serving continuously as co-chair of the Prize Selection Committee since 2006. She has also led the establishment of the Beacon Award for Women Leaders in Oncology in 2022, recognizing outstanding women pioneers who have significantly impacted cancer patients worldwide through developing and commercializing novel technologies and implementing public policy.
Dr. Ba led the establishment of the AIM-HI Women’s Venture Competition in 2020, a first-of-its-kind program providing lifeline seed investment, critical coaching, and valuable networking opportunities for women entrepreneurs. She has led the investment into 20+ early-stage oncology companies since 2019.
Dr. Ba received the NBC4 WORKING 4 THE COMMUNITY Award in 2019, the inaugural Outstanding Achievement Award for international cooperation from the Society for Neuro-Oncology of the Chinese Medical Doctor Association in 2017, and the Inaugural CRS WOMEN IN SCIENCES Award in 2011. She was named one of the “Top 300 Women Leaders in Global Health” in 2015 by the Graduate Institute of International and Development Studies’ Global Health Programme.
Dr. Ba has served on the Women in Science Committee of CRS (Control Release Society) since 2017. She is also a Member of Springboard’s Life Science Council, a group of experts worldwide in biotech, pharma, medical devices, and health IT who invest their “human capital” in Springboard’s pipeline of high-growth, women-led companies. She is the former President of the Chinese Biopharmaceutical Association (2010-2011) and a lifetime member of BayHelix, an invitation-only organization of leaders of Chinese origin involved globally in life sciences and health.
Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.